A Study to Assess Primarily the Tolerability and Safety of SAR439794 After Repeated Sublingual Daily Administration in Peanut Allergic Adult and Adolescent Patients

NCT03463135 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Food Allergy

Interventions

DRUG: Glucopyranosyl Lipid A (GLA)
DRUG: Sublingual Immuno Therapy (SLIT) Peanut Extract (PE)
DRUG: Placebo for GLA
DRUG: Placebo for SLIT PE

Sponsor

Sanofi